THANK YOU, PARTICIPANTS!
The HERO Research team is pleased to share with you interim results from HERO-TOGETHER, a post-COVID-19 vaccine observational study. These results were submitted to the U.S. Food and Drug Administration (FDA) and includes data collected during the first six months, December 2020 to June.

WHY IS THIS RESEARCH IMPORTANT? Data and experiences from participants in clinical trials who received a COVID-19 vaccine was used by drug companies when seeking Emergency Use Authorization (EUA) of the vaccines by the FDA. After EUA authorization, continuing to collect experiences after vaccination will help us understand the long-term health effects and efficacy of COVID-19 vaccines.

WHERE ARE PARTICIPANTS FROM? HERO-TOGETHER participants represent all 50 states plus the District of Columbia.

ABOUT THE HERO REGISTRY
HERO-TOGETHER is one of the research opportunities available through the Healthcare Worker Exposure Response & Outcomes (HERO) Registry. The Registry is a community of people who share what it is like to work and live during the COVID-19 pandemic. The HERO Registry is open to healthcare workers, their families, and community members.

WHO IS INVOLVED? This first report included data from 7,824 people who received the first dose of a COVID-19 vaccine within 60 days of joining the study.

MEAN AGE 43 years
FEMALE 66%
WHITE OR CAUCASIAN 72%
HISPANIC OR LATINO 5%
PREGNANT AT TIME OF FIRST DOSE 3%

TOP 5 HEALTHCARE WORKER ROLES
1. Registered Nurse
2. Physician
3. Resident/Fellow
4. Physician Assistant
5. Nurse Practitioner

WHAT'S NEXT? HERO-TOGETHER participants will continue to share their experiences for up to 2 years after receiving the vaccine. The team will continue to provide interim reports of additional study data to the FDA.

Once all study data is collected, the HERO Research team will analyze the information and share results with participants, HERO Registry members, regulatory agencies, the scientific community, and the public.

The HERO Registry is funded through a Patient-Centered Outcomes Research Institute Award. The program is coordinated by the Duke Clinical Research Institute and leverages PCORnet®, the National Patient-Centered Clinical Research Network.

Funding for the HERO-TOGETHER study is provided by Pfizer, including the online platform operated by a company called Verily. All study activities are overseen by the Duke Clinical Research Institute.